ADIMMUNE CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.35 TWD | -4.04% |
|
+3.01% | -17.50% |
| Sales 2022 | 2.25B 69.24M | Sales 2023 | 1.79B 54.89M | Capitalization | 13.97B 430M |
|---|---|---|---|---|---|
| Net income 2022 | 291M 8.95M | Net income 2023 | -640M -19.68M | EV / Sales 2022 | 6.43 x |
| Net cash position 2022 | 695M 21.37M | Net Debt 2023 | 673M 20.68M | EV / Sales 2023 | 8.2 x |
| P/E ratio 2022 |
52.4
x | P/E ratio 2023 |
-21.8
x | Employees | 564 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.73% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.04% | ||
| 1 week | +3.01% | ||
| Current month | +2.24% | ||
| 1 month | +2.43% | ||
| 3 months | -11.92% | ||
| 6 months | -14.40% | ||
| Current year | -17.50% |
1 week
25.00
29.90
1 month
25.0029.90
Current year
25.0033.75
1 year
25.0041.10
3 years
25.0064.80
5 years
19.0079.80
10 years
14.4079.80
| Managers | Title | Age | Since |
|---|---|---|---|
Chung Cheng Liu
CEO | Chief Executive Officer | - | 19-06-19 |
Yin Teng Chang
DFI | Director of Finance/CFO | - | 20-12-31 |
Chi Hsien Chan
CHM | Chairman | - | 08-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung Chin Lin
BRD | Director/Board Member | 70 | 19-06-19 |
Hsiao Po Hsu
BRD | Director/Board Member | - | 11-08-14 |
Chi Hsien Chan
CHM | Chairman | - | 08-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -1.55% | - | |
| 0.00% | 34 M€ | +1.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 27.35 | -4.04% | 2,121,740 |
| 24-04-18 | 28.5 | +2.52% | 7,751,243 |
| 24-04-17 | 27.8 | +9.88% | 2,178,635 |
| 24-04-16 | 25.3 | -2.69% | 1,422,019 |
| 24-04-15 | 26 | -2.07% | 1,077,173 |
End-of-day quote Taiwan S.E., April 18, 2024
More quotes
ADIMMUNE CORPORATION is a Taiwan-based company principally engaged in the research and development, processing, manufacture and trading of influenza vaccine products and non-flu vaccine products. The Company's products include Japanese encephalitis vaccines, tetanus vaccines, influenza vaccines, H1N1 influenza vaccines and tuberculin. The vaccine products are applied in the prevention of various infectious viruses. The tuberculin is applied in tuberculin purified protein derivative (PPD) test. The Company distributes its products within domestic market and to overseas markets, including other markets in Asia, Europe and Africa.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.50% | 354M | |
| -5.99% | 83.66B | |
| +2.76% | 40.41B | |
| -24.88% | 28.26B | |
| +53.61% | 24.53B | |
| -8.08% | 16.82B | |
| -33.74% | 13.39B | |
| -16.63% | 11.75B | |
| -11.19% | 11.69B | |
| -2.25% | 8.13B |
- Stock Market
- Equities
- 4142 Stock
